Clinical TrialsEquillium received a positive recommendation from the Independent Data Monitoring Committee (IDMC) based on its review of the interim results from the Phase 3 EQUATOR study evaluating itolizumab in subjects with acute graft-vs.-host disease (aGVHD).
Financial PerformanceIf Ono Pharmaceutical Co. Ltd. exercises its option on itolizumab, this would result in a payment of ¥5B—roughly $32.2M based on recent exchange rates—and significantly improve Equillium's balance sheet strength.
Product DevelopmentEQ101 recently reported positive topline data from an open-label study, exceeding KOL's expectations in severe patients and indicating proof-of-concept in alopecia with a 20% response rate.